Detalhe da pesquisa
1.
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Gynecol Oncol
; 154(2): 314-322, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31204078
2.
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
J Neurooncol
; 140(2): 317-328, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30073642
3.
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
Haematologica
; 100(3): 336-44, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25480499
4.
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Cancer
; 119(22): 4036-43, 2013 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24006085
5.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
J Clin Oncol
; 41(15): 2815-2826, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36888930
6.
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
J Clin Oncol
; 40(5): 481-491, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914545
7.
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Clin Cancer Res
; 27(12): 3360-3369, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33568344
8.
Antibody buffering of systemically administered lysozyme.
Eur J Haematol
; 84(3): 252-8, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19922461
9.
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Clin Lung Cancer
; 21(5): 455-463.e4, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586767
10.
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
J Immunother Cancer
; 7(1): 274, 2019 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31647026
11.
Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.
JAMA Ophthalmol
; 137(1): 96-100, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383154
12.
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Clin Cancer Res
; 25(20): 6061-6072, 2019 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31358540
13.
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Lung Cancer
; 128: 105-112, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30642441
14.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
JAMA Oncol
; 5(1): 74-82, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30242306
15.
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
Leukemia
; 32(5): 1157-1167, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29479065
16.
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
JAMA Oncol
; 4(4): 537-544, 2018 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29423515
17.
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Eur J Cancer
; 101: 201-209, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30077125
18.
Antibody buffering in the brain.
J Mol Biol
; 364(5): 1003-9, 2006 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17045608
19.
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response.
Clin Cancer Res
; 26(10): 2436, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414763
20.
Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
Expert Rev Hematol
; 7(4): 427-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24871925